Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
| ▸ | RORC | P51449 | 9/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29718685 | 1.00 | AKR1B1 (0.67) | AKR1B1PTGS2RORCRXRARXRB | |
| SCHEMBL29718776 | 0.85 | KMT2A (0.46) | AKR1B1PTGS2RORCTYK2L3MBTL1 | |
| SCHEMBL109215 | 0.81 | AKR1B1 (1.00) | AKR1B1PTGS2KDM4EMEN1LMNA | |
| SCHEMBL909428 | 0.81 | PTGS2 (0.54) | AKR1B1PTGS2RORCRXRARXRB | |
| SCHEMBL18302050 | 0.79 | AKR1B1 (0.47) | AKR1B1PTGS2RXRARXRBRXRG | |
| SCHEMBL15524368 | 0.79 | AKR1B1 (0.43) | AKR1B1PTGS2RORCRXRARXRB | |
| SCHEMBL18301971 | 0.79 | AKR1B1 (0.52) | AKR1B1PTGS2RORCRXRARXRB | |
| Hydrochloric Acid SCHEMBL1374156 | 0.79 | AKR1B1 (0.95) | AKR1B1PTGS2KDM4EMEN1LMNA | |
| SCHEMBL9364446 | 0.79 | AKR1B1 (0.95) | AKR1B1PTGS2KDM4EMEN1LMNA | |
| SCHEMBL12812210 | 0.78 | TAAR1 (0.41) | AKR1B1PTGS2RORCTYK2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524938-B2 | Aromatic sulfonamide derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220324807-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| EP-3763704-A1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2021-01-13 | — | — | EP | disclosed |
| US-10844016-B2 | Aromatic sulfonamide derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-11-24 | — | — | US | disclosed |
| EP-3458443-B1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma AG (DE) | 2020-08-19 | — | — | EP | disclosed |
| EP-3204359-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2020-07-01 | — | — | EP | disclosed |
| EP-3204359-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2020-07-01 | — | — | EP | disclosed |
| US-20190119210-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-04-25 | — | — | US | disclosed |
| EP-3458443-A1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2019-03-27 | — | — | EP | disclosed |
| CN-109415321-A | aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2019-03-01 | — | — | CN | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| EP-3204359-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2017-08-16 | — | — | EP | disclosed |
| CN-107001278-A | Tetrahydro isoquinoline derivative | UCB生物制药私人有限公司 | 2017-08-01 | — | — | CN | disclosed |
| WO-2016198374-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| US-4426536-A | Synthesis of phenylacetic acid esters | ELI LILLY AND COMPANY (US) | 1984-01-17 | — | — | US | disclosed |
| EP-0098058-A1 | Synthesis of phenylacetic acid esters | ELI LILLY AND COMPANY (US) | 1984-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119210-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | AKR1B1 859/4885PTGS2 2521/4885RORC 412/4885 |
| US-20220324807-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | AKR1B1 859/4885PTGS2 2521/4885RORC 412/4885 |
| US-11524938-B2 | Aromatic sulfonamide derivatives | ARSA, SULT2A1, TPST2 | AKR1B1 859/4885PTGS2 2521/4885RORC 412/4885 |
| US-10844016-B2 | Aromatic sulfonamide derivatives | ARSA, SULT2A1, TPST2 | AKR1B1 859/4885PTGS2 2521/4885RORC 412/4885 |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | OPRD1, ADRA1D, GPR52 | AKR1B1 1371/4885PTGS2 2125/4885RORC 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.